Case Study: U.S. Roche Genentech improves psychosocial risk insights and action planning with meQuilibrium

U.S. Roche Genentech reaches 50% survey response rate with meQuilibrium

U.S. Roche Genentech, a global healthcare leader with a strong culture of well-being, sought to improve its annual global assessment of psychosocial risk in the workplace. The company's existing report was comprehensive but difficult to act upon. They partnered with vendor meQuilibrium (meQ) to leverage its Workforce Intelligence platform to streamline the process and make the findings more actionable.

meQuilibrium implemented a customized, evidence-based survey to measure key risk domains across the organization. The solution achieved a phenomenal 50% response rate from 34,000 employees and contractors. meQ's platform then provided flexible reporting that identified specific risks for different job functions, enabling targeted mitigation. This allowed U.S. Roche Genentech to precisely deploy meQ's resilience training resources to address the root causes of issues like burnout, anxiety, and depression.

U.S. Roche Genentech